Zeda Zhang, PhD

Damon Runyon Cancer Research Foundation Fellow at Memorial Sloan Kettering Cancer Center, New York, NY

Zeda Zhang, PhD

Damon Runyon Cancer Research Foundation Fellow at Memorial Sloan Kettering Cancer Center, New York, NY
Zeda Zhang

Lab Phone


Lab Fax


Start Year


End Year



BS, Zhongshan University

Where there is great patience, care, and perseverance, there can be discovery. I learned that in my very first research experience, and the discovery of the unknown — particularly in my current area of interest, cancer biology — motivated me to pursue a PhD at Gerstner Sloan Kettering. Not only is it the best cancer program but also everyone is friendly and helpful. It is simultaneously great fun and a scientifically inspired environment.


The NCI Predoctoral to Postdoctoral Fellow Transition Award (NCI F99/K00) (2017-2019)


Szeglin BC, Wu C, Marco MR, Park HS, Zhang Z, Zhang B, Garcia-Aguilar J, Beauchamp RD, Chen XS, Smith JJ. (2022) A SMAD4-modulated gene profile predicts disease-free survival in stage II and III colorectal cancer. Cancer Rep. Epub 2021

Mao N, Zhang Z, Lee YS, Choi D, Rivera AA, Li D, Lee C, Haywood S, Chen X, Chang Q, Xu G, Chen HA, de Stanchina E, Sawyers C, Rosen N, Hsieh AC, Chen Y, Carver BS. (2021) Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. Nat Commun.

Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida W, Linton E, Lee E, Barnes SD, Chen HA, Mao N, Wongvipat J, Choi D, Chen X, Zhao H, Manova-Todorova K, de Stanchina E, Taplin ME, Balk SP, Rathkopf DE, Gopalan A, Carver BS, Mu P, Jiang X, Watson PA, Sawyers CL. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. 2020 Aug 10;38(2):279-296.e9. doi: 10.1016/j.ccell.2020.06.005. Epub 2020 Jul 16. PMCID: PMC7472556.

Zhang Z, Zhou C, Li X, Barnes SD, Deng S, Hoover E, Chen CC, Lee YS, Zhang Y, Wang C, Metang LA, Wu C, Tirado CR, Johnson NA, Wongvipat J, Navrazhina K, Cao Z, Choi D, Huang D, Huang CH, Linton E, Chen X, Liang Y, Mason CE, de Stanchina E, Abida W, Lujambio A, Li S, Lowe SW, Mendell JT, Malladi VS, Sawyers CL, Mu P. (2020) Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell 34, 584-598

Mao N, Gao D, Hu W, Gadal S, Hieronymus H, Wang S, Sullivan P, Zhang Z, Choi D, Rosen N, Sawyers CL, Gopalan A, Chen Y, Carver BS. (2020) Oncogenic ERG represses PI3K signaling through down-regulation of IRS2. Cancer Res. pii: canres.1394.2019 [Epub ahead of print]

Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, Watson PA, Davicioni E, Sboner A, Barbieri CE, Bose R, Leslie CS, Sawyers CL (2019) FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. doi: 10.1038/s41586-019-1318-9. [Epub ahead of print].

Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, Wongvipat J, Wasmuth EV, Shah N, Sullivan PS, Doran MG, Wang P, Patruno A, Zhao Y; International SU2C/PCF Prostate Cancer Dream Team, Zheng D, Schultz N, Sawyers CL. (2017) ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature 546, 671-675. PMCID: PMC5576182 [Available on 2018-06-29]

Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, Huang CH, de Stanchina E, Lowe SW, Ellis L, Beltran H, Rubin MA, Goodrich DW, Demichelis F, Sawyers CL. (2017) SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355, 84-88. PMCID: PMC5247742 [Available on 2017-04-06]

Gao D, Zhan Y, Di W, Moore AR, Sher JJ, Guan Y, Wang S, Zhang Z, Murphy DA, Sawyers CL, Chi P, Chen Y.(2016) A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon. PLoS One 11, 0161084. PMCID: PMC4990297

View a full listing of Zeda Zhang’s journal articles.